Selective androgen receptor modulator has anti-tumor effects in ER-positive breast cancer patients

1 minute, 46 seconds Read

A research paper published today (8 February 2024). Lancet Oncology Evidence that the drug Enoboserm, a selective androgen receptor modulator that stimulates male sex hormone receptors, has anti-tumor effects in estrogen-receptor-positive breast cancer patients.

Lead author Professor Carlo Palmieri, from the University of Liverpool and The Clatterbridge Cancer Center NHS Foundation Trust, said: “These results are very encouraging – we have shown that the use of enoboserm in advanced/metastatic breast cancer can result in clinical benefit, and this is the first clinical evidence that a non-estrogen receptor regimen with a selective androgen receptor modulator can result in clinical benefit. This is pre- Building on the clinical evidence we published in Nature Medicine.”

For at least 40 years, treatment for this type of breast cancer has focused on directly targeting and inhibiting estrogen receptor activity. This new study therefore tested a completely different approach.

The orally administered drug enoboserm is a selective androgen receptor modulator, which can stimulate androgen receptor activity in breast cancer. Androgen receptor is a tumor suppressor in estrogen receptor positive breast cancer.

A multi-site international study led by Dr Beth Overmyer of the Dana-Farber Cancer Institute of Boston USA evaluated the efficacy and safety of enoboserm in 136 postmenopausal women with locally advanced or metastatic ER-positive, HER2-negative breast cancer (HER2). A protein called human epidermal growth factor receptor 2, which promotes the growth of cancer cells). Enoboserm has anti-tumor effects, as well as being tolerated without significant impact on quality of life.

“These data support further development and evaluation of the efficacy of enoboserm and other agents that stimulate the androgen receptor for the treatment of AR-positive, ER-positive, HER2-negative advanced breast cancer.”

Complete study A Phase 2 Open-Label Randomized Study of Enoboserm, a New Oral, 1 Selective Androgen Receptor Modulator, in Androgen Receptor-Positive, Estrogen Receptor-Positive, and HER2-Negative Advanced Breast Cancer Available at Lancet Oncology.


Journal Reference:

Palmieri, C., etc (2024) Activity and safety of enoboserm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, estrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomized, open-label, multicenter multinational Parallel design, phase 2 trial. Lancet Oncology.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *